Particle.news
Download on the App Store
5 ARTICLES
·
last mo.

Germline‑Targeting HIV Vaccine Elicits Broadly Neutralizing Antibodies in Primates

The priming-and-booster regimen offers proof of principle for steering rare B cells to make bnAbs and points to further human testing and booster optimization.

Image
Image

Overview

  • A Nature paper reports that the vaccine produced bnAb‑class memory B cells in about half of rhesus macaques and measurable serum broadly neutralizing antibody activity in roughly 44% of animals.
  • The vaccine uses a germline‑targeting approach that first activates rare naive B cells with a priming immunogen and then guides their maturation with a planned sequence of heterologous booster shots.
  • In the strongest responder, antibody levels reached titers the authors say could be protective against diverse HIV strains, but the study did not test whether vaccinated animals were actually protected from infection.
  • The priming immunogen has prior human evaluation in HVTN 144 and is currently in the Phase I IAVI G004 trial, and researchers are now focused on improving booster sequences and raising the proportion of responders.
  • The result caps about 14 years of CHAVD design work and gives a new, testable vaccine strategy, but key hurdles remain including uncertain protection correlates, suboptimal response rates, and the need for rigorous human efficacy trials.